Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
81 participants
INTERVENTIONAL
2003-09-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Summary Background Data: For sake of safety and to avoid excessive blood loss during parenchymal transection, vascular inflow occlusion is an effective trick but may cause ischemic damage to the remnant liver and can lead to liver failure in case of chronic liver disease. IPTC has been proven to be superior to continuous hepatic pedicle clamping as it preserve liver remnant from severe ischemia/reperfusion lesion, so does IPC. Yet, if IPC is beneficial if liver resection is performed under IPTC has never been demonstrated in a randomised controlled trial (RCT). The investigators designed a RCT to assess the impact of IPC in patient undergoing major liver resection with intermittent vascular inflow occlusion.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Infrahepatic Inferior Vena Cava Clamping Versus Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping
NCT02405416
Intraductal Transanastomotic Stent in Duct-to-duct Biliary Reconstruction in Liver Transplantation
NCT04804215
Reversible Portal Vein Embolization Before Major Hepatectomy
NCT02945059
A Trial of Complete Versus Selective HepaticVascular Clamping in Hepatectomy
NCT00851968
Comparison Between Pre and Intraoperative ERCP in Treatment of Common Bile Duct Stones
NCT01046552
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Anaesthetic protocol:
Patients' status was evaluated by the ASA (American Society of Anaesthesiology) scoring system. Surgical procedure was conducted under low central venous pressure (5cm H2O) to avoid excessive bleeding from suprahepatic veins backflow.13 Patients' anaesthesia was performed using a single protocol that was common to all participating centres. Patients in whom this protocol was contraindicated due to medical reasons were excluded. A standardized general anesthesia using thiopental, sufentanil, atracurium and sevoflurane was applied throughout the study period. Mechanical ventilation was carried out using 50 % oxygen in nitrous oxide and was adjusted to keep end-tidal PCO2 between 4.7 and 6.0 kPA. Intra-venous cefazolin (Cephazolin, PANPHARMA laboratory, FOUGERES, France) was administered for antibioprophylaxy. An arterial line was inserted for arterial pressure monitoring and blood sampling. Central venous pressure was not consistently maintained below a predetermined level. Intraoperative Ringer lactate infusion was limited to the minimum, practically below 500 mL, until parenchymal resection was completed. Following liver resection, hydroxyethyl starch 130 (Voluven, Fresenius laboratory, SEVRES, France), 20 mL/kg, was infused in one hour. Thereafter, additional hydroxyethyl starch, fresh frozen plasma, red blood cell packs were administered as indicated by urinary output, hemodynamics, and biological data. Thresholds for blood transfusion were a hemoglobin level of 7g/dL for healthy patients 64 years of age or under, and 9 g/dL for patients 65 years of age or over and/or with preexisting cardiopulmonary disease (1).
Surgical protocol:
All of the patients included in this study were operated in high volume centres by senior surgeons specialized in hepatobiliary surgery. Major resection was defined as resection of 3 or more liver segment as described by Couinaud. Ischemic preconditioning was performed through a sequence of 10 minutes vascular inflow occlusion and 10 minutes of reperfusion prior to intermittent pedicular clamping. Intermittent pedicle clamping was conducted through a sequence of 15 minutes of vascular inflow occlusion and 5 minutes of reperfusion. Intermittent clamping was used during the whole parenchyma transection process. During ischemic preconditioning the liver left in native position to avoid ischemic process due to compression. Surgical liver biopsies were performed before after interruption of the vascular inflow. The samples were all collected in the same centre (Cochin Hospital) for histological and molecular biological analysis. The device used for clamping was left to the surgeon's discretion (Tourniquet or vascular clamp) but had to be the same for both preconditioning and clamping. The technique used for parenchymal liver transection was left to the surgeon's discretion as well as haemostasis and BILIOSTASIS techniques which were performed using bipolar forceps, metallic clips or ligation depending on vessels or bile ducts size. Devices used for parenchymal transection and haemostasis/BILIOSTASIS techniques were recorded in the preoperative data collection form. Postoperative drainage of the abdominal cavity was left to the surgeon's discretion but was collected in the data sheet. All complications occurring during surgery were collected as well as blood loss, blood transfusion and fluid infusion.
Patient's follow-up and data collection:
Patients' follow-up was 3 months and was initiated the day before surgery (Di). Given that primary hypothesis was a 50% reduction of transaminases (AST, ALT) level on postoperative day 1 in the preconditioning group, blood samples were collected on all patients on Di and POD1 for transaminases measurement. All of these samples were collected in a unique biochemistry laboratory (Hospital Cochin) to avoid inter laboratory variations. Besides these two samples, each centres conducted a regular biological follow-up of patients on a previously established schedule which was common to all centres. Biological assessment was performed on blood samples collected on Di and POD 1, 3, 5, 7, 14 and 28. Blood samples were tested for liver biochemistry (AST, ALT, PAL, GGT, BT and BC), prothrombin time, factor V, blood cells count (red blood cells, white blood cells and platelets) and albumine. Clinical examination was performed every day by the senior surgeon in charge of the patients until they were discharge from hospital, as well as on POD 15, POD 30 (5 days) and POD 90 (10 days). All impaired outcomes were noted in the data sheets. Surgical complications collected were: Intra abdominal bleeding, biliary fistula, vascular complication, intra abdominal abscess, wound infection and reintervention. Medical complication collected were: Infection (urinary tract, lung, catheter) liver dysfunction, liver failure, ascitis, pleural fluid effusion necessitating a drainage or not. Postoperative morbidity and mortality were defined as any impaired surgical or medical outcome or death occurring within POD 90, respectively. When hospital readmission was required patients where hospitalised in the surgical department. Finally histological analysis of the liver samples collected at surgery was reviewed by a single pathologist who was unaware of any clinical data.
Statistical analysis:
The analysis was performed in intention-to-treat. The sample size calculation was based on the primary endpoint postoperative (POD1) aspartate aminotransferase (ALT). According to previous data (ref 4-7,9,10 protocol), the sample size calculation was performed with the expectation of a 50% difference in postoperative serum ALT level with a level of statistical significance of 0.05 and a power of 0.80, using a two-tailed t-test. This calculation indicated to include 38 patients in each group. Modification of ALT was also quantified as the difference between Di and POD 1. Demographic data, baseline characteristics, and surgical data are summarized by groups using descriptive statistic. Categorical variables are expressed as numbers (percentages) and comparisons between groups were performed by the chi-square test or Fisher exact test, when needed. Continuous variables are expressed as mean (standard deviation of the mean (sd)) and were compared using two-tailed t-test. Analyses were performed using SAS software, version 9.1, SAS institute inc, Cary, North Carolina.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Preconditioning
Surgery with ischemic preconditioning
Preconditioning ischemia
Surgery with a preconditioning ischemia
Control
Surgery without preconditioning ischemia
Control
Surgery without preconditioning surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Control
Surgery without preconditioning surgery
Preconditioning ischemia
Surgery with a preconditioning ischemia
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* liver resection of 3 segments (as described by Couinaud) or more,
* posterior lesionectomy (segment VI and VII),
* liver resection only or associated with a primary digestive or biliary tumor.
* Portal vein embolisation allowed
Exclusion Criteria
* synchronous radiofrequency or cryotherapy ablation,
* undergoing segmentectomy,
* left lateral lesionectomy or laparoscopic liver resection,
* pregnant women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
URC-CIC Paris Descartes Necker Cochin
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olivier Scatton, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Cochin
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Scatton O, Zalinski S, Jegou D, Compagnon P, Lesurtel M, Belghiti J, Boudjema K, Lentschener C, Soubrane O. Randomized clinical trial of ischaemic preconditioning in major liver resection with intermittent Pringle manoeuvre. Br J Surg. 2011 Sep;98(9):1236-43. doi: 10.1002/bjs.7626. Epub 2011 Jul 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AOR01010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.